Objective: To study the frequency of neurological disorders associated to HIV infection. Methods: This cross-sectional study was carried out from 16th June to 16th September 2014 and included all 289 HIV-outpatients admitted to the Parakou University hospital. All data were recorded, physical examination was performed and the medical sheet of each patient was assessed. The diagnosis of neurological disorder (central and peripheral) was based on clinical features, past medical history, biological test and CT-scan data after multidisciplinary staff. Epi-data and Epi-Info 6.04C were used to perform analysis. Results: They were 73 (25.3%) male with a mean age of 38.0 years +/− 10.1 years. The mean duration of disease was 48.5 months +/− 37.1 months. 150 (51.9%) of them were at Stage 3 of the disease. All patients (99.7%) were infected by HIV1, 188 (76.1%) had CD4 cells at the onset of the follow-up less than 350 cells/mm 3 and 260 (90.0%) were on ART. Among the 289 patients, 110 had at least one neurological disorder, the frequency of neurological disorders was 38.1%. The main neurological disorders were peripheral neuropathy (34.3%), isolated headache (5.2%), stroke (0.7%), cerebral toxoplasmosis (0.7%) and one case of dementia (0.7%). The main associated factors were the age of patient and exposure on neurotoxic drug, especially ART. Conclusion: The neurological disorders were more frequent among HIV patients with a high frequency of peripheral neuropathy probably due to ART.
Introduction
In sub-Saharan Africa, Human Immunodeficiency Virus (HIV) prevalence is 4.7% [1] . According to the WHO, from 2000 to 2020, worldwide HIV-related deaths will be estimated at 68 million, including 55 million in Africa [2] . Since the discovery of the first case in 1985 in Benin, HIV/AIDS prevalence has grown exponentially and hovered around 1.1% in 2012 [3] . Neurological damage associated with HIV infection is common. In previous studies neurological disorders accounted for more than 50% [4] . We reported previously 42.4% of the prevalence of distal sensory polyneuropathy among the HIV outpatients in Parakou [5] . In Bobo-Dioulasso at Burkina Faso Millogo and al reported 14% of neurological disorders in HIV patients [6] . They can occur at all stages of HIV infection and can affect the central nervous system, as well as peripheral nervous system and muscle. This study was conducted with main objective to study the frequency and factors associated with neurological complications of HIV infection in people living with HIV followed ambulatory at CHUD-B/A in Parakou in 2014.
Methods of Study
Type of study and period of collection: This was a descriptive and analytical cross-sectional study with prospective data collection from 16 June to 16
September 2014.
Population of study is people living with HIV followed in ambulatory basis in consultation on the care site.
We included patient HIV positive, age more than 15 years old who had given their consent.
Criteria of exclusion were pregnant women infected with HIV and subject who was not able to answer questions.
Sampling was exhaustive with a size of 289 inclusive subjects.
The main dependent variable is neurological complication, whatever the type.
After a clinical examination doing by the senior neurologist, study of file and after a validation in staff by a colleague of specialists (neurologist, internist, radiologist), a secondary endpoint is the type of neurological complication whose terms are 3 = certain, 2 = probable, 1 = possible, 0 = no neurological complication, 9 = not researched. Table 1 
Results

Sociodemographic Characteristics
The 
Clinical Characteristics
According to the WHO stages, twenty six percent of patients were in stage 1 of HIV Table 2 .
Thus 16 patients had a sensory syndrome (5.5%), 10 patients a peripheral neurogenic syndrome (3.5%), 1 patient a dementia (0.3%), 1 patient a meningitis syndrome (0.3%) and 1 patient an intracranial hypertension syndrome (0.3%). Two hundred and seventy nine (96.5%) of patients were taking bactrim prophylaxis; 260 (90%) were on antiretroviral therapy. The therapeutic regimens are summarized in Table 3 . AZT = Zidovudine, 3TC = Lamivudine, EFV = Efavirenz, NVP = Nevirapine, ABC = Abacavir, TDF = Tenofovir, LPV/r = Lopinavir/Ritonavir.
Neurological Complications and Factors Associated
The frequency of neurological complication was 38.1% (110 patients). Diagnosis of these complications was probable in 12.2%, possible in 2.8% and certain in 19.4% of cases. They are summarized in Table 4 .
The factors associated to the neurological complications were: age with a frequency of complications at 26% in the 25 -34 years group and 49.3% in the >45 years group (Chi 2 = 15.53; p = 0.0014); and neurotoxic treatments (p = 0.018 Chi 2 = 5.53). ART (p = 0.5351) and the CD4 cells count (p = 0.76) were not statistically associated with the frequency of neurological complications.
Nevertheless, the mean CD4 count in patients with toxoplasmosis was 190 cells/mm 3 and 310.5 cells/mm 3 in patients with peripheral neuropathy. 
Time of Onset of Neurological Complications According to the Duration of HIV Infection and CD4 Cells Count (Figure 1)
Persistent headaches are the first neurological manifestations that appear on average at 42 months after the discovery of HIV infection.
Persistent headaches, dementia and neuropathies are the first neurological manifestations that appear after ARV therapy. Their mean time to onset was 37 months, 41 months and 47 months respectively after ART.
The comparison of average duration of infection, mean duration of ART, mean CD4 count and mean age according to neurological or non-neurological complications is summarized in Table 5 . The patients with neurological disorders were elder than those without neurological disorders and had a long duration of the disease.
Discussion
Patients were young, as patients living with HIV in sub-Saharan Africa [6] .
However, the prevalence of neurological complications increased with age in this study. Average age of patients with neurological complications 40.7 years [7] . Prevalence of neurological complications in our patients is mainly related to the use of neurotoxic drugs, especially stavudine, which is the most widely used molecule. In our study, stage of HIV is not associated with neurological complications, and the proportion of patients with neurological complications is not statistically different from the proportion of other patients.
Polyneuropathy (PN) is due to longer duration of infection, uncontrolled viremia, and exposure to older ARV including d4T, ddI and ddC [8] but new regimens suggest a stability of PN prevalence over time [9] . These are the most frequent neurological complications (34.26%) in our patients. Millogo in Burkina Faso had noted a frequency around 37% [6] and Wateba in Togo 30.7% [10] . These neurological manifestations occur more than 4 years and a half in the course of the disease, and their only imputability to neurotoxicity by stavudine or to HIV remains debatable in lack of electroneuromyographic exploration and nerve biopsy. The frequency of cerebral toxoplasmosis is low in this population, as they were included only in consultation and the majority of our patients were on cotrimoxazol prophylaxis (96.5%). Both HIV infection and ART could potentially increase an individual's risk of stroke [11] . In France, its incidence is 1.1 per 1000 person-years (Male = 1.4 Female = 0.5) [12] . In this study, stroke occurred more late in the course of the disease (197 months) with a lower freqency 0.7% but justify systematic HIV test in all cases of stroke, especially in developing countries such as ours. Isolated headaches are the second most common complication in our patients; probably because of the side effects of ART mainly AZT used in most patients (67.9%).
Conclusion
The frequency of neurological complications in people living with HIV aged 15 years and over followed by outpatient visits in Parakou CHUDB in 2014 is 38.1%. A predominance of peripheral neuropathies was noted. Clinical, electrophysiological and therapeutic cohort studies are needed to better monitor this population in our country.
